SCINAI IMMUNOTHERAPEUTICS LTD. Proceeds from Debt, Net of Issuance Costs
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Proceeds from Debt, Net of Issuance Costs of $1.69 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-05-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2024-05-15
- SCINAI IMMUNOTHERAPEUTICS LTD. proceeds from debt, net of issuance costs for fiscal 2022 was $932.00K, a 95.65% decline from fiscal 2021.
- SCINAI IMMUNOTHERAPEUTICS LTD. proceeds from debt, net of issuance costs for fiscal 2021 was $21.43M.
| Period end | Proceeds from Debt, Net of Issuance Costs | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|
| 2023-12-31 | $1.69M 20-F · filed 2024-05-15 | ||
| 2023-09-19 | $1.33M 20-F · filed 2024-05-15 | ||
| 2022-12-31 | $932.00K 10-K · filed 2023-04-17 | ||
| 2022-06-30 | $6.00K 6-K/A · filed 2023-08-18 | ||
| 2021-12-31 | $21.43M 10-K · filed 2023-04-17 |